Ligand Enters into License and Supply Agreements with Amgen

Ligand Pharmaceuticals Incorporated

Represented Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) in with its License and Supply Agreements with Amgen, a leading biopharmaceutical company, for the development and global commercialization of Captisol-enabled AMG 330 against acute myeloid leukemia. Read the press release.

Ligand is a biopharmaceutical company that focuses on developing and/or acquiring technologies that help pharmaceutical companies in discovering and creating medicines.

San Diego-based Hayden Trubitt represented Ligand Pharmaceuticals in this transaction.